Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$115.45 USD

115.45
135,153

-6.63 (-5.43%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $115.48 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates

Mirum's (MIRM) earnings and revenues miss estimates in the first quarter of 2024. Livmarli drives year-over-year sales.

Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues

Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.

Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down

Viatris (VTRS) Q1 numbers fall short of estimates. The company adjusts the annual guidance to reflect the impact of divestitures.

CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss

CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.

Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?

Here is how Ligand Pharmaceuticals (LGND) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.

Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss

Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.

Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues

Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.

Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates

Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.

Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates

Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.

Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues

Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.

Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss

Beam Therapeutics (BEAM) reports mixed first-quarter results. The company remains focused on pipeline development.

Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates

Halozyme (HALO) reports mixed first-quarter 2024 earnings. The company maintains revenue guidance for 2024.

Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow

Dr. Reddy's (RDY) posts better-than-expected fiscal fourth-quarter results on growth in global generics revenues in North America as well as Emerging Markets.

Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus

Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.

Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates

Ligand (LGND) delivered earnings and revenue surprises of 6.19% and 4.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates

Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.

Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil

Rocket Pharmaceuticals' (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.

Perrigo (PRGO) Q1 Earnings Surpass, Sales Miss Estimates

Perrigo (PRGO) reports mixed first-quarter 2024 results. Management reiterates its financial outlook for 2024.

Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat

Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.

Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales

Vertex's (VRTX) first-quarter earnings and revenues surpass estimates. Higher sales of Trikafta/Kaftrio in U.S. and ex-U.S. markets drive the top line.

Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand

BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.

Shaun Pruitt headshot

Don't Overlook These Top Medical Stocks as Q1 Earnings Approach

Several top-rated Zacks Medical sector stocks are standing out ahead of their quarterly reports on Tuesday, May 7.

Ekta Bagri headshot

5 Biotech Stocks Worth Adding to Your Portfolio in 2024

New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.

Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.

Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates

Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.